Mangafodipir Trisodium

CHEMBL2096651 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
757.3 g/mol
LogP
Phase
4

A trisodium form of mangafodipir with the same therapeutic properties. A manganese-based contrast agent previously used during MRI scans to enhance the visibility of liver and pancreatic lesions, helping to distinguish tumors from normal tissue.

น้ำหนักโมเลกุล

757.3000 g/mol

TPSA

303.00 Ų

ด้านการรักษา

กลไกการออกฤทธิ์

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

[H+].[H+].[H+].CC1=NC=C(C(=C1[O-])CN(CCN(CC2=C(C(=NC=C2COP(=O)([O-])[O-])C)[O-])CC(=O)[O-])CC(=O)[O-])COP(=O)([O-])[O-].[Na+].[Na+].[Na+].[Mn+2]

InChI

InChI=1S/C22H32N4O14P2.Mn.3Na/c1-13-21(31)17(15(5-23-13)11-39-41(33,34)35)7-25(9-19(27)28)3-4-26(10-20(29)30)8-18-16(12-40-42(36,37)38)6-24-14(2)22(18)32;;;;/h5-6,31-32H,3-4,7-12H2,1-2H3,(H,27,28)(H,29,30)(H2,33,34,35)(H2,36,37,38);;;;/q;+2;3*+1/p-5

Molecular Formula

C22H27MnN4Na3O14P2

HBD / HBA

3 / 18

พันธะที่หมุนได้

13

อะตอมหนัก

46

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

A trisodium form of mangafodipir with the same therapeutic properties. A manganese-based contrast agent previously used during MRI scans to enhance the visibility of liver and pancreatic lesions, helping to distinguish tumors from normal tissue.

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Yes, Mangafodipir Trisodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2096651. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 160036. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.